Olaparib Approved for BRCA Mutated MBC

Options
Bestbird
Bestbird Member Posts: 2,818
edited January 2018 in Stage IV/Metastatic Breast Cancer ONLY

Patients with germline (inherited) BRCA1 or BRCA2 mbc that is HER2 negative have been granted a new therapeutic option in addition to therapies based on their cancer subtype.

In January 2018, the FDA approved Olaparib (Lynparza) for use by patients with germline BRCA-mutated, HER-2-negative metastatic breast cancer who were previously treated with chemotherapy.

Olaparib is an oral polymerase (PARP) inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation.In a randomized Phase 3 study of 302 HER2 negative mbc patients with germline BRCA mutations who had received no more than 2 prior chemotherapy regimens, olaparib was compared with a single-agent therapy of the physician's choice.Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months); and the response rate was 59.9% in the olaparib group and 28.8% in the standard-therapy group.
· Share on FacebookShare on Twitter

Comments

  • SandiBeach57
    SandiBeach57 Member Posts: 1,617
    edited January 2018

    Thank you for posting.

    · Share on FacebookShare on Twitter
  • Zillsnot4me
    Zillsnot4me Member Posts: 2,687
    edited January 2018

    Question. Does the BRAC have to be inherited? It's my understanding that I have the mutation but no family history so not inherited.

    I know my MO said new stuff was coming down the pike and he ran several genetic tests. My next scan and appt is Feb.

    Im not overly fond on my current regime -xeloda but still working on the dosage.

    Thanks for keeping us update. You truly are the BEST bird.

    · Share on FacebookShare on Twitter
  • Ashlyn
    Ashlyn Member Posts: 141
    edited January 2018

    I hope that this will be available in Canada soon (drugs take a long time to be reviewed here) ...I have an acquired BRCA signature (not hereditary) ...it's not in my blood but in the tumour itself. I have read that PARPs could benefit up to 20% more women who are BRCA neg but have some kind of somatic BRCA mutation / signature in the cancer.

    Thanks for sharing this info!

    · Share on FacebookShare on Twitter

Categories